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Abstract
Background: Mitochondrial oxidative phosphorylation (OXPHOS) via the respiratory chain is required for the
maintenance of tumour cell proliferation and regulation of epithelial to mesenchymal transition (EMT)-related
phenotypes through mechanisms that are not fully understood. The essential mitochondrial import protein coiled-
coil helix coiled-coil helix domain-containing protein 4 (CHCHD4) controls respiratory chain complex activity and
oxygen consumption, and regulates the growth of tumours in vivo. In this study, we interrogate the importance of
CHCHD4-regulated mitochondrial metabolism for tumour cell proliferation and EMT-related phenotypes, and
elucidate key pathways involved.
Results: Using in silico analyses of 967 tumour cell lines, and tumours from different cancer patient cohorts, we
show that CHCHD4 expression positively correlates with OXPHOS and proliferative pathways including the mTORC1
signalling pathway. We show that CHCHD4 expression significantly correlates with the doubling time of a range of
tumour cell lines, and that CHCHD4-mediated tumour cell growth and mTORC1 signalling is coupled to respiratory
chain complex I (CI) activity. Using global metabolomics analysis, we show that CHCHD4 regulates amino acid
metabolism, and that CHCHD4-mediated tumour cell growth is dependent on glutamine. We show that CHCHD4-
mediated tumour cell growth is linked to CI-regulated mTORC1 signalling and amino acid metabolism. Finally, we
show that CHCHD4 expression in tumours is inversely correlated with EMT-related gene expression, and that
increased CHCHD4 expression in tumour cells modulates EMT-related phenotypes.
Conclusions: CHCHD4 drives tumour cell growth and activates mTORC1 signalling through its control of respiratory
chain mediated metabolism and complex I biology, and also regulates EMT-related phenotypes of tumour cells.
Keywords: Coiled-coil helix coiled-coil helix domain-containing protein 4 (CHCHD4), hypoxia, HIF-1α, mitochondria,
respiratory chain, disulfide relay system, complex I, tumour growth, tumour metabolism
Introduction
Rapidly dividing tumour cells require specific metabo-
lites to support proliferation, and the metabolic rewiring
of malignant cells contributes both to transformation
and tumour progression [1]. One of the earliest observa-
tions of metabolic adaptation in tumour cells came from
the work of Otto Warburg, who identified that even in
the presence of sufficient oxygen, many cancer cells
consumed high concentrations of glucose and secreted
high levels of lactate [2]. In addition to oncogene-driven
increases in glucose consumption, tumour cells also in-
crease their consumption of glutamine [3], as glutamine
provides carbon and nitrogen moieties for amino acid and
nucleotide synthesis. Despite the prevalence of oxidative
fermentation in transformed cells, tumour cells retain
their oxidative mitochondrial machinery to support the
catabolism of glucose and glutamine for the production of
macromolecules to permit cell division [4, 5]. Indeed, a
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variety of recent studies have demonstrated that while the
availability of adenosine triphosphate (ATP) is unlikely to
be a limiting factor for the proliferation of tumour cells
[6–8], the availability of amino acids and nucleotides can
be important depending on the cellular context [8–12].
However, our understanding of the mechanisms by which
transformed cells maintain biosynthesis of macromole-
cules for cell division remains incomplete. Delineating the
pathways which support tumour cell proliferation are of
great interest for the development of new therapeutic
strategies, and anti-tumour agents which inhibit nucleo-
tide synthesis (e.g. fluorouracil) have been used clinically
for decades [13]. Therapies which target amino acid
synthesis are emerging in clinical development, and are
showing promise [14–16].
Mitochondria support cellular proliferation by supplying
ATP for the bioenergetic demands of the cell through
OXPHOS, and are also the site of reactions which supply
the cell with precursors for the synthesis of macromole-
cules such as DNA, proteins and lipids [17]. In addition,
complex I (CI) of the respiratory chain regulates the intra-
cellular NADH/NAD ratio, which is itself an essential
cofactor for biosynthetic reactions which support prolifer-
ation [18]. Depletion of mitochondrial DNA in tumour
cells (ρ0 cells) inhibits tumour cell proliferation and
tumorigenesis in vitro and in vivo, demonstrating the im-
portance of mitochondria in a cancer setting [19–21]. Fur-
thermore, CI-inhibiting biguanidines (e.g. metformin) are
effective in slowing the growth of tumour cells in vitro
[22, 23], and are under investigation in clinical trials as ad-
juvant therapies for cancer patients.
All but 13 subunits of the respiratory chain complexes
are encoded by nuclear genes, and must be imported
across the mitochondrial membrane(s) for complex
assembly to take place. Several import and sorting path-
ways exist in the mitochondria which are essential for
respiratory chain activity [24]. One such pathway, the
disulfide relay system (DRS), is responsible for the im-
port and oxidative folding of small intermembrane space
(IMS) proteins, which include subunits of CI and CIV, as
well as assembly factors for CIII and CIV [25–27]. The
substrate-binding oxidoreductase of the DRS is the
redox-sensitive protein CHCHD4, which we have shown
to regulate cellular oxygen consumption rate, and
hypoxia-inducible factor (HIF) signalling [28–30]. We
have shown that increased CHCHD4 expression in
tumours correlates with increased tumour progression,
and is associated with decreased patient survival and dis-
ease recurrence [28]. In this study, we investigate the
molecular mechanisms by which CHCHD4 controls
tumour cell proliferation through its effects on mito-
chondrial metabolism. Using gene set enrichment ana-
lysis (GSEA) to identify key tumour-related pathways
associated with CHCHD4 expression that are linked to
OXPHOS and tumour proliferation, we investigate the
role of CHCHD4 in regulating tumour cell growth,
mTORC1 signalling, amino acid metabolism and EMT-
related phenotypes.
Results
CHCHD4 expression positively correlates with OXPHOS
and proliferative pathways in tumours
Recently, we have shown that elevated CHCHD4 expres-
sion in tumour cells increases tumour cell proliferation
irrespective of oxygen levels [30]. To better understand
the relationship between CHCHD4 and tumour cell
proliferation, we carried out GSEA on genes that were
significantly correlated with CHCHD4 expression in
transcriptomic data from a panel of 967 tumour cell
lines (Novartis/Broad Institute Tumour Cell Line En-
cyclopaedia). As anticipated, CHCHD4 was significantly
co-expressed with genes from an OXPHOS gene set
(HALLMARK_OXIDATIVE_PHOSPHORYLATION,
Broad Institute) (Fig. 1a), including subunits of CI
(NDUFS3) and CIV (COX7C) (Additional file 1: Figure
S1a). Interestingly, many of the most significantly
enriched gene sets correlated with CHCHD4 expression
were those from proliferative signalling pathways regu-
lated by known oncogenes, such as MYC and mTORC1
(Fig. 1a). Genes regulated by mTORC1 signalling that
were most significantly correlated with CHCHD4
expression include cell-cycle regulators (CDC25A,
CCNF) and subunits of DNA polymerases (POLR3G)
(Additional file 1: Figure S1b). We next carried out
GSEA on genes that were significantly co-expressed with
CHCHD4 in tumours from different cancer patient
cohorts using transcriptomic data available from The
Cancer Genome Atlas (http://portal.gdc.cancer.gov/).
Again, we found that CHCHD4 expression was signifi-
cantly associated with genes involved in OXPHOS in
colon adenocarcinoma (Fig. 1b), breast cancer (Fig. 1c)
and glioblastoma (Additional file 1: Figure S1c) patient
samples. In colon adenocarcinoma (Fig. 1d) and breast
cancer patient samples (Fig. 1e), the most highly corre-
lated genes involved in OXPHOS constituted components
of respiratory chain complexes (e.g. UQCRH, NDUFAB1),
as well as enzymes of the TCA cycle (DLAT, FH), and a
variety of other genes that encode proteins involved in
general maintenance of mitochondrial function (e.g.
TOMM70, HSPA9). As we observed for our GSEA of
tumour cell lines (Fig. 1a), CHCHD4 expression was also
most highly correlated with the expression of genes regu-
lated by proliferative signalling pathways including MYC
and mTORC1, in tumours from each of the cancer patient
cohorts analysed (Fig. 1b, c, Additional file 1: Figure S1c).
Genes regulated by mTORC1 signalling that were associ-
ated with CHCHD4 expression in colon adenocarcinoma
patient samples included cell cycle regulators (CCNA2,
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CDC25A), and genes that encode proteins involved in nu-
cleotide synthesis (MTHFD2L). Together, these data indi-
cate that across a broad range of tumour cell lines and
diverse tumour types, CHCHD4 expression is positively
associated with OXPHOS, and key proliferative pathways
such as the mTORC1 signalling pathway.
CHCHD4-mediated tumour cell growth and mTORC1
signalling is coupled to CI activity
Our in silico analyses demonstrated a positive associ-
ation between CHCHD4 expression, OXPHOS and pro-
liferative pathways in tumour cell lines and patient
tumour samples (Fig. 1). Thus, we next investigated the
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Fig. 1 CHCHD4 expression positively correlates with OXPHOS and proliferative pathways in tumours. a Chart shows GSEA of genes positively
correlated with CHCHD4 expression in Novartis/Broad Institute Cancer Cell Line Encyclopedia RNASeq data. n = 967 cell lines. b, c Charts show
GSEA of genes positively correlated with CHCHD4 expression in colon adenocarcinoma (b) and breast cancer (c) patient tumours. d Heatmap of
selected genes from the HALLMARK_OXIDATIVE_PHOSPHORYLATION gene-set (Broad Institute) that are positively correlated with CHCHD4
expression in colon adenocarcinoma patient tumours. e, f Heatmap of selected genes from the HALLMARK_MTORC1_SIGNALLING gene-set
(Broad Institute) that are positively correlated with CHCHD4 expression in colon adenocarcinoma (e) and breast cancer (f) patient tumours
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relationship between CHCHD4-mediated regulation of
OXPHOS and tumour cell growth. To do this, we used
U2OS cells stably expressing wild-type CHCHD4
[CHCHD4 (WT)-expressing cells, clones WT.cl1,
WT.cl3], or stably expressing a mutant form of
CHCHD4 in which the substrate-binding cysteines of
the CPC motif have been mutated to alanines (C66A/
C68A) described by us previously [28–30]. Consistent
with our previous study [30], we found that elevated
CHCHD4 expression led to increased expression of indi-
vidual subunits of CI (NDUFS3), CII (SDHA), CIII
(UQCRC2) and CIV (COXIV) (Fig. 2a). Importantly, ex-
pression of the C66A/C68A mutant form of CHCHD4,
which we and others have shown is defective in import
function and mitochondrial localisation [28, 31], did not
lead to increased mitochondrial expression of these re-
spiratory chain subunits (Fig. 2a). Notably, we and others
have shown that loss of CHCHD4 leads to reduced
levels of apoptosis-inducing factor (AIF) [30, 32, 33], a
CHCHD4-interacting protein [33]. However, we found
no obvious effect on the expression of AIF in CHCHD4
overexpressing cells (Additional file 2: Figure S2a).
We and others have shown that CHCHD4 is a critical
regulator of CI expression [30, 33]. Further examination
of CI activity using an in-gel nitrotetrazolium blue assay
demonstrated increased CI activity in mitochondrial ex-
tracts from CHCHD4 (WT)-expressing cells (WT.cl1,
WT.cl3), while whole CI activity was reduced in
CHCHD4 (C66A/C68A)-expressing cells, compared to
control U2OS cells (Fig. 2b). CI catalyses the first step of
NADH oxidation, providing the cell with NAD+ which
acts as an essential cofactor for TCA cycle enzymes, and
enzymes involved in amino acid and nucleotide biosyn-
thesis. Using live cell imaging of NADH fluorescence
[34] (Additional file 2: Figure S2b), we found that
CHCHD4 (WT)-expressing cells exhibited lower basal
NADH fluorescence compared with control U2OS cells
(Fig. 2c, Additional file 2: Figure S2b), indicating higher
CI activity in live cells with elevated CHCHD4 expres-
sion, consistent with our in-gel assay for CI activity
(Fig. 2b).
Using stable isotope labelling with amino acid in cell
culture (SILAC) and proteomic analysis of CHCHD4
(WT)-expressing cells, we have recently shown that
CHCHD4 expression in tumour cells is a critical deter-
minant of the expression of a broad range of respiratory
chain subunits including numerous subunits of CI [30].
Analysis of our SILAC data showed the most signifi-
cantly enriched proteins in CHCHD4 (WT)-expressing
cells compared to control cells were those regulated by
the mTORC1 signalling pathway (e.g. GPI, E2F1)
(Fig. 2d), consistent with our GSEA of tumour cell lines
and patient tumour samples (Fig. 1a–c). As mTORC1 is
a potent regulator of proliferation [35], we next assessed
the effects of exogenous expression of CHCHD4 on the
proliferation rates of U2OS cells. Consistent with our
recently published study [30], we found that elevated ex-
pression of CHCHD4 in the CHCHD4 (WT)-expressing
cells led to a small but significant increase in growth
rates over 72 h compare to control U2OS cells (Fig. 2e).
However, exogenous expression of mutant (C66A/C68A)
CHCHD4 did not affect growth rate (Fig. 2e).
We hypothesised that CHCHD4 may regulate a CI-
mTORC1-proliferation axis, and so we next investigated
the influence of CHCHD4 expression on mTORC1
signalling in the absence or presence of respiratory chain
inhibitors. The mTORC1 signalling pathway regulates
cell growth and protein synthesis in part by directly
phosphorylating p70S6 kinase 1 (p70S6K) [35]. Both
basal p70S6K and protein translation rates (as assessed
by puromycin incorporation) were consistently elevated
in CHCHD4 (WT)-expressing cells compared to control
cells (Fig. 2f ) indicating higher basal mTORC1 activity.
mTORC1 signalling was blocked by the GI50 dose of the
CI inhibitors, rotenone (500 nM) and BAY 87-2243
(50 nM), while only puromycin incorporation was sensi-
tive to inhibition of CIV (Fig. 2f, Additional file 2: Figure
S2c), suggesting that CI and CIV influence protein
translation through distinct mechanism(s). Consistently,
we have shown that CHCHD4 expression confers in-
creased sensitivity to growth inhibition by inhibitors of
CI, such as rotenone and BAY 87-2243 (Fig. 2g) [30, 36],
but not inhibitors of CIV [30]. To investigate whether
the increased sensitivity conferred by CHCHD4 overex-
pression was due specifically to the loss of the NADH
dehydrogenase activity of CI, we generated pools of con-
trol U2OS and CHCHD4 (WT)-expressing cells stably
expressing a rotenone-insensitive NADH dehydrogenase
from yeast (NDI1), or the empty expression vector
(pWPI) (Additional file 2: Figure S2d). NDI1 expression
was capable of significantly reducing the sensitivity of
both control U2OS cells (p = 0.005) and CHCHD4
(WT)-expressing cells (p = 0.001) to growth inhibition in
the presence of BAY 87-2243 (Fig. 2g). Importantly,
NDI1 expression rendered CHCHD4 (WT)-expressing
cells resistant to BAY 87-2243 to the same degree as
control U2OS (pWPI expressing) cells (p = 0.09)
(Fig. 2g). This indicates that the increased sensitivity of
CHCHD4 expressing cells to CI inhibitors is dependent
on the loss of NADH dehydrogenase activity in these
cells. Collectively, our data suggest CHCHD4-mediated
tumour cell growth and mTORC1 signalling is coupled
to CI activity.
CHCHD4 expression links growth rate to CI activity and
mTORC1 signalling in tumour cells
To further investigate the positive association between
CHCHD4 expression, CI and mTORC1 signalling (Figs. 1
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Fig. 2 (See legend on next page.)
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and 2), we next examined a panel of tumour cell lines to
determine whether cells exhibited differing dependencies
on CI activity for growth. To do this, we selected six
well-known tumour cell lines derived from different tis-
sues (colon, cervix, bone, breast, brain and prostate),
each with a different genetic background, and each
exhibiting a different relative growth rate (Fig. 3a). To
characterise the dependency of these cell lines on
OXPHOS for growth, we assessed their relative sensitiv-
ity to respiratory chain inhibition using titrations of the
CI inhibitors, rotenone (Fig. 3b) and BAY 87-2243 (Add-
itional file 3: Figure S3a), and the CIII inhibitor antimy-
cin A (Additional file 3: Figure S3b). Sensitivity to these
agents was inversely correlated with the relative growth
rates of these cell lines (Fig. 3c), demonstrating the com-
mon importance of respiratory chain activity for tumour
cell growth. We next assessed CHCHD4 expression
levels in two cell lines from our panel, one with a high
growth rate and increased sensitivity to rotenone
(HCT116 colon carcinoma, GR50 = 42.4 ± 6.3 nM), and
one with a lower growth rate and reduced sensitivity to
respiratory chain inhibition (U2OS osteosarcoma,
GR50 = 341 ± 101 nM). Interestingly, CHCHD4 expres-
sion levels were higher in HCT116 cells compared to
U2OS cells both at the transcript level (Fig. 3d) and pro-
tein level (Fig. 3e). Furthermore, expression of subunits
from each of the respiratory chain complexes (CI-IV)
was higher in HCT116 cells compared to U2OS cells
(Fig. 3e), as was basal oxygen consumption rate (Fig. 3f ),
demonstrating increased respiratory chain activity. These
data indicate a link between CHCHD4 expression levels,
OXPHOS and tumour cell growth across a range of
tumour cell types with different aetiologies and onco-
genic drivers. In fact, we also found that CHCHD4
expression was weakly but significantly inversely corre-
lated with the doubling times of 368 different tumour
cell lines from the Cancer Cell Line Encyclopedia
(CCLE, Broad Institute) (Additional file 3: Figure S3c).
As our GSEA of tumour cell lines identified the
mTORC1 signalling pathway as positively associated
with CHCHD4 expression (Fig. 1a), next we compared
the effects of respiratory chain inhibition on mTORC1
signalling in HCT116 and U2OS cells. Basal mTORC1
signalling was not apparently different between HCT116
and U2OS cells as assessed by p70S6K phosphorylation,
and puromycin incorporation (Fig. 3g). Consistently there
was a larger reduction in both p70S6K phosphorylation
and puromycin incorporation in HCT116 cells with
rotenone treatment compared to U2OS cells (Fig. 3g).
These data indicate that mTORC1 signalling in HCT116
cells is more sensitive to CI inhibition (Fig. 3g), similar
to U2OS cells overexpressing CHCHD4 (Fig. 2f ), further
supporting a link between CHCHD4 expression, CI and
mTORC1 signalling. It is known that CI, through the
production of NAD+ from the oxidation of NADH, can
promote the synthesis of asparagine which directly acti-
vates mTORC1 signalling [35], and that aspartate, which
is required for the de novo synthesis of nucleotides, can
also directly activate mTORC1 signalling [37, 38]. In-
deed, we found that supplementation of aspartate (D) to
the media of both HCT116 and U2OS cells partially res-
cued the reduced mTORC1 signalling observed in the
presence of rotenone (Fig. 3g). Collectively, our data
suggest that CHCHD4 expression links growth rate to
CI activity, mTORC1 signalling and amino acid metabol-
ism in tumour cells.
CHCHD4-mediated tumour cell growth is linked to CI-
regulated mTORC1 signalling and amino acid metabolism
Based on our data thus far (Figs. 1, 2 and 3), we
hypothesised that CHCHD4-mediated regulation of re-
spiratory chain activity stimulates tumour cell growth
through the promotion of biosynthetic pathways. In the
case of CI, increased activity promotes favourable NAD/
NADH ratios for the biosynthesis of amino acids such as
aspartate via the TCA cycle (Fig. 4a). Our NADH mea-
surements showed decreased basal intracellular NADH
levels (relative to the total NADH/NAD pool) (Fig. 2c,
Additional file 2: Figure S2b) alongside increased CI ac-
tivity in CHCHD4 (WT)-expressing cells compared to
control U2OS cells (Fig. 2b). We therefore next carried
out metabolomics analysis to assess the effects of
CHCHD4 expression on the cellular metabolome, with
particular focus on TCA cycle intermediates and amino
(See figure on previous page.)
Fig. 2 CHCHD4-mediated tumour cell growth and mTORC1 signalling is coupled to CI activity. a Western blots show levels of CHCHD4, NDUFS3
(CI), SDHA (CII) UQCRC2 (CIII), COXIV (CIV) in whole cell lysates of control (Ctrl) U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1) or CHCHD4-
(C66A/C68A)-expressing cells (C66A/C68A). α-Tubulin was used as a load control. b In-gel NTB assay of CI activity in mitochondrial fractions
isolated from control U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells (C66A/C68A). c Basal
NADH fluorescence (as % of total NADH/NAD pool) in control U2OS cells or CHCHD4 (WT)-expressing cells (WT.cl1). ± SD. n = 3. d Chart shows
GSEA of proteins upregulated in CHCHD4 (WT)-expressing cells (WT.cl1) relative to control U2OS cells, as assessed by SILAC [30]. n = 3. e Chart
shows relative growth rates of cells described in (b) at 72 h relative to 0 h. ± SD. n = 3. f Western blots show levels of phosphorylated (P-) and
total (T-) p70S6K, and puromycin labelled polypeptides in control U2OS cells and CHCHD4 (WT)-expressing cells (WT.cl1) either untreated (NT), or
treated with rotenone (500 nM), BAY 87-2243 (50 nM) or sodium azide (100 μM) for 24 h. β-Actin was used as a load control. g Chart shows
relative growth of control U2OS cells, and CHCHD4 (WT)-expressing cells (WT.cl1) stably expressing an empty vector (pWPI) or yeast NDI1, treated
with BAY 87-2243 using a 10-fold dilution curve (starting dose 100 nM) for 72 h. ± SD. n = 3
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acids. CHCHD4 (WT)-expressing cells and control
U2OS cells were cultured with uniformly labelled 13C5-
glutamine, followed by analysis of both the isotopologue
composition and total pool sizes of key glutamine-
derived metabolites. We found that intracellular levels of
glutamine and other glutamine-derived metabolites were
lower in CHCHD4 (WT)-expressing cells compared to
control U2OS cells (Fig. 4b). Conversely, the
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Fig. 3 CHCHD4 expression links growth rate to CI activity and mTORC1 signalling in tumour cells. a Chart shows the growth rates of a panel
of tumour cell lines over 72 h. ± SD. n = 3. b Chart shows growth of tumour cell lines described in (a) treated with 100 nM rotenone for 72 h,
relative to untreated (0 nM) cells. ± SD. n = 3. c Chart shows xy scatter of the fold change in growth of indicated tumour cell lines at 72 h vs 0h,
compared to their relative growth rate when treated with 100 nM rotenone. Trend line (dashed blue) and R2 value (Spearman’s correlation)
shown. d Chart shows relative abundance of CHCHD4 transcripts measured by QPCR in HCT116 and U2OS cells. CHCHD4 expression is relative to
ACTB and normalised to CHCHD4 transcript levels in HCT116 cells. ± SD. n = 3. e Western blots show levels of CHCHD4, NDUFB10 (CI), SDHA (CII)
UQCRC2 (CIII), COXIV (CIV) in whole cell lysates of HCT116 and U2OS cells. β-Actin was used as a load control. f Chart shows basal OCR of HCT116
and U2OS cells, measured by Seahorse respirometry. ± SD. n = 3. g Western blots show levels of phosphorylated (P-) and total (T-) p70S6K,
puromycin labelled polypeptides in HCT116 and U2OS cells treated as indicated for 24 h. β-Actin was used as a load control. Relative band
intensities of P-p70S6K indicated
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Fig. 4 CHCHD4-mediated tumour cell growth is linked to CI-regulated mTORC1 signalling and amino acid metabolism. a Schematic of proposed
model of CHCHD4-regulated CI-dependent amino acid (AA) metabolism and influence on tumour cell growth. b Chart shows relative intracellular
abundance of selected metabolites from metabolomics analysis in CHCHD4 (WT)-expressing cells (WT.cl1) relative to control U2OS cells.
Representative of 2 experiments. ± SD. n = 5. c Chart shows relative proportions of isotopically labelled metabolites in control U2OS cells and
CHCHD4 (WT)-expressing cells (WT.cl1). Representative of 2 experiments. n = 5. d Western blots show levels of phosphorylated (P-), total (T-)
p70S6K and puromycin labelled polypeptides in control U2OS cells and CHCHD4 (WT)- expressing cells (WT.cl1) treated as indicated for 8 h. β-
Actin was used as a load control. Relative band intensities of P-p70S6K indicated. e Images of control U2OS cells and CHCHD4 (WT)-expressing
cells (WT.cl1, WT.cl3) cultured to confluency in the presence of glutamine (6 mM), and 3 days later following removal of glutamine (0 mM). f
Western blots show levels of phosphorylated (P-) and total (T-) p70S6K, and puromycin labelled polypeptides in control U2OS cells and CHCHD4
(WT)-expressing cells (WT.cl1) treated either in the absence (−) or presence (+) of 50 nM BAY 87-2243 for 24 h, supplemented with 10 mM
aspartate (D) or 1 mM NAD. β-Actin was used as a load control. g Charts show relative growth of control U2OS cells and CHCHD4 (WT)-
expressing cells (WT.cl1) treated with 10 nM BAY 87-2243 in the absence or presence of 10 mM aspartate (D) or 1 mM NAD for 72 h. ± SD. n = 3
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extracellular levels of glutamine were not significantly
different (Additional file 4: Figure S4), suggesting that
rates of intracellular glutamine consumption were higher
in CHCHD4 (WT)-expressing cells compared to control
U2OS cells. There were only very minor differences in
the isotopologue composition of a selection of these metab-
olites (Fig. 4c), indicating that there was no significant
change in the routes of glutamine (and other amino acid)
consumption in CHCHD4 (WT)-expressing cells compared
to control U2OS cells. We hypothesised that by increasing
CI expression and activity, elevated CHCHD4 expression
was stimulating amino acid biosynthesis, leading to in-
creased mTORC1 activity, protein synthesis rates and thus
increased consumption of glutamine-derived amino acids
(such as aspartate and asparagine). We therefore next
tested whether glutamine was required for the increased
mTORC1 signalling and protein synthesis in CHCHD4
(WT)-expressing cells. Glutamine withdrawal led to a larger
reduction in both p70S6K phosphorylation and puromycin
incorporation in CHCHD4 (WT)-expressing cells (Fig. 4d),
indicating that glutamine metabolism was required to sup-
port the increased mTORC1 activity in these cells. Indeed,
supplementation with aspartate was capable of partially res-
cuing mTORC1 activity on withdrawal of glutamine
(Fig. 4d). Furthermore, CHCHD4 (WT)-expressing cells
were lost more rapidly from culture on withdrawal of glu-
tamine than control U2OS cells, indicating a higher de-
pendency on glutamine for their proliferation and survival
(Fig. 4e). As we hypothesised that the CI-mediated stimula-
tion of amino acid metabolism may in part underpin the in-
creased mTORC1 activity and proliferation of CHCHD4
(WT)-expressing cells (Fig. 4a), we next assessed whether
aspartate or NAD supplementation could rescue mTORC1
activity and the proliferation of cells treated cells with the
CI inhibitor BAY 87-2243. Both aspartate and NAD supple-
mentation were capable of partially rescuing p70S6K phos-
phorylation and puromycin incorporation in the presence
of BAY 87-2243 (Fig. 4f). Furthermore, both aspartate and
NAD (Fig. 4g) were capable of partially rescuing the
growth of both CHCHD4 (WT)-expressing cells and con-
trol U2OS cells treated with BAY 87-2243. Interestingly,
while CHCHD4 (WT)-expressing cells were more sensi-
tive to BAY 87-2243 treatment, both aspartate and NAD
supplementation were able to more significantly rescue
the growth of CHCHD4 (WT)-expressing cells compared
to control U2OS cells treated with BAY 87-2243 (Fig. 4g).
Together, these data demonstrate that CHCHD4 expres-
sion regulates amino acid metabolism, which in part un-
derpins CHCHD4-mediated tumour cell growth and CI-
regulated mTORC1 signalling.
CHCHD4 regulates the EMT phenotype of tumour cells
Along with identifying significantly upregulated gene
profiles associated with increased CHCHD4 expression
(Fig. 1), interestingly, our GSEA also showed that
(EMT)-related genes were amongst the most signifi-
cantly downregulated genes associated with increased
CHCHD4 expression. This was also the case in our
SILAC dataset from CHCHD4 (WT)-expressing cells
(Fig. 5a, b), as well as our analysis of transcriptomic data
from patient samples (Additional file 5: Figure S5a, b)
and tumour cell lines (Additional file 5: Figure S5c).
Downregulated EMT-related genes included those en-
coding the essential cytoskeletal protein vimentin, and
the extracellular matrix (ECM) binding protein N-
cadherin (CDH2), both of which are well-characterised
markers of EMT (Fig. 5b) [39]. Furthermore, the inter-
mediate cytoskeleton filament and mesenchymal-
epithelial transition (MET) marker keratin-18 (KRT18,
[40]) was the second most upregulated protein identified
in our SILAC analysis (Fig. 5b). We confirmed some of
these EMT protein expression changes in CHCHD4
(WT)-expressing cells, while these proteins were un-
changed in CHCHD4 (C66A/C68A)-expressing cells
compared to controls (Fig. 5c and Additional file 5: Fig-
ure S5d). We found similar results in HCT116 cells
(which do not express detectable levels of vimentin
[41]), where overexpression or silencing of CHCHD4 in-
creased or decreased the expression of the MET marker
E-cadherin respectively (Additional file 5: Figure S5e, f ).
Furthermore, we found that the transcript levels of VIM
and KRT18 were downregulated and upregulated re-
spectively in cells overexpressing CHCHD4 (Fig. 5d),
suggesting that the changes in EMT gene expression are
at the level of transcription and that elevated CHCHD4
expression in tumour cells leads to a transcriptional sup-
pression of EMT-related genes. Importantly, CHCHD4
(WT)-expressing cells had a lower migratory capacity in
a 2D scratch-wound assay compared to both control and
CHCHD4 (C66A/C68A)-expressing cells (Fig. 5e, f ).
Recent studies have connected mitochondrial metabol-
ism and health to the EMT phenotype of cultured cells,
through changes in cytoskeletal organisation, adhesion
and motility [42]. Indeed, it has long been appreciated
that cell proliferation and motility are inversely related,
both in physiology and disease [43–45]. Vimentin is an
intermediate filament protein which regulates cell motil-
ity through association with other cytoskeletal proteins
to promote pseudopodia formation at the cell periphery
[46]. Immunofluorescent staining of vimentin and im-
aging of control U2OS, and CHCHD4 (WT)-expressing
cells demonstrated that the cytoplasmic localisation of
vimentin was affected by CHCHD4 expression, as it ap-
peared to exhibit a more perinuclear distribution in
CHCHD4 (WT)-expressing cells compared to control
U2OS cells (Fig. 5g, Additional file 5: Figure S5 g). This
redistribution of vimentin has previously been identified
as a consequence of MET [47, 48]. To investigate
Thomas et al. Cancer & Metabolism             (2019) 7:7 Page 9 of 17
ac
e f
g h
d
b
Fig. 5 CHCHD4 regulates the EMT phenotype of tumour cells. a Chart shows GSEA of downregulated proteins detected in SILAC analysis of
CHCHD4 (WT)-expressing cells (WT.cl1), compared to control U2OS cells. n = 3. b Volcano plot shows relative expression of all proteins detected
in SILAC analysis of CHCHD4 (WT)-expressing cells (WT.cl1) compared to control (Ctrl) U2OS cells [30]. Selected genes highlighted. n = 3. c
Western blots show levels of vimentin and N-cadherin in control (Ctrl) U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3) and CHCHD4
(C66A/C68A)-expressing cells (C66A/C68A). β-Actin was used as a load control. d Chart shows relative transcript levels of VIM, KRT18 and CHCHD4
detected by Q-PCR in control U2OS cells and CHCHD4 (WT)-expressing cells (WT.cl1). ± SD. n = 3. e Images show a scratch-wound assay of
control (Ctrl) U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1) and CHCHD4 (C66A/C68A)-expressing cells (C66A/C68A) at 0 h and 24 h. White
lines denote width of scratch-wound. f Chart shows % wound closure at 24 h relative to 0 h in images shown in (e). ± SD. n = 3. g
Immunofluorescence images of vimentin distribution in control U2OS cells and CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3). h
Immunofluorescence images of vimentin distribution in control U2OS cells and CHCHD4 (WT)-expressing cells (WT.cl1) either untreated (NT) or
treated with 50 nM rotenone for 72 h
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whether the CHCHD4-mediated effects on changes in
vimentin intracellular distribution were related to in-
creased CI activity, we treated both control U2OS and
CHCHD4 (WT)-expressing U2OS cells with rotenone,
and assessed vimentin localisation by immunofluores-
cence. Rotenone treatment led to the redistribution of
vimentin from the perinuclear region to the cytoplasm
in CHCHD4 (WT)-expressing cells, phenocopying the
vimentin distribution in control U2OS cells (Fig. 5h,
Additional file 5: Figure S5g). Together, these data show
that elevated CHCHD4 expression in tumour cells nega-
tively correlates with EMT-related gene expression in
normoxia, and reduces 2D cell migration. In addition,
CHCHD4-mediated regulation of vimentin localisation
is dependent on CI activity.
Discussion
Dysregulated metabolism is a common feature of tumour
cells, and numerous oncogenes are potent regulators of
metabolic pathways that contribute to tumour cell prolif-
eration. The mechanisms by which tumour cells maintain
biosynthesis of macromolecules for division are incom-
pletely understood and are currently the focus of intensive
investigation. Here, we have identified CHCHD4 as a new
regulator of the metabolic drive which supports tumour
cell proliferation, in part through its effects on respiratory
chain-mediated metabolism. We have also shown through
in vitro and in silico analysis that CHCHD4 expression is
positively associated with the activity of proliferative sig-
nalling pathways, such as the mTORC1 pathway in many
different tumour cell lines and patient tumour samples.
Additionally, our GSEA identified other proliferative path-
ways that were associated with CHCHD4 expression, such
as MYC and E2F. MYC is a well-characterised and com-
monly deregulated oncogene [49], is a potent regulator of
mitochondrial metabolism and biogenesis [50], and like
CHCHD4 collaborates with HIF signalling under certain
contexts [51]. However, GSEA can be confounded by the
promiscuity of common genes between different gene sets
[52], and the mTORC1, MYC and E2F pathways are
known to regulate the expression of common genes.
Nevertheless, these analyses suggest that the influence of
CHCHD4 on proliferation may impinge on multiple path-
ways with clinical relevance, which warrants further
investigation.
Mitochondria promote proliferation in part through
ATP synthesis, but tumour cells can adapt their metab-
olism to decrease their dependence on OXPHOS for
ATP homeostasis, and upregulate non-mitochondrial
pathways of ATP synthesis, such as glycolysis and anaer-
obic fermentation of pyruvate [53, 54]. Besides ATP syn-
thesis, mitochondria are also important metabolic hubs
for pathways that support biomass accumulation, and
these pathways appear to be more acutely sensitive to
perturbations in respiratory chain function than ATP
synthesis. Indeed, here, we found that doses of the CI in-
hibitor BAY 87-2243 that are insufficient to block OCR
[30] were capable of significantly influencing protein
translation and tumour cell proliferation. In support of
the essential role of mitochondrial metabolism for
biomass accumulation, previous studies have demon-
strated that the synthesis of aspartate is an essential
function of mitochondrial respiration for proliferating
cells [8, 10]. In agreement with these studies, we show
here that aspartate supplementation is capable of par-
tially reversing the anti-proliferative effects of both CI
inhibition and glutamine withdrawal, and stimulates
mTORC1-mediated activation of translation. Since this
rescue by aspartate supplementation was only partial, we
conclude that other biosynthetic pathways that depend
on respiratory chain activity must also contribute to
tumour cell proliferation. For example, both (CI-derived)
NAD and glutamine are directly involved in nucleotide
synthesis [18, 55, 56], and nucleotide supplementation in
addition to aspartate supplementation may be necessary
to fully recapitulate the proliferation of cells treated with
CI inhibitors or glutamine withdrawal. Moreover,
pyrimidine synthesis through the uridine salvage path-
way relies directly on respiratory chain activity, through
the action of the mitochondrial enzyme dihydroorotate
dehydrogenase (DHODH) [57]. In cells depleted of mito-
chondrial DNA (ρ0 cells), supplementation with uridine
is necessary to rescue the loss of proliferative capacity
[58], demonstrating that supporting nucleotide synthesis
is an essential role of the mitochondria for proliferating
cells. Indeed, transcriptome analysis of patient samples
has identified that upregulation of nucleotide biosyn-
thetic genes is one of the most common metabolic
alterations across cancer types [52, 59].
Cancer can be considered a disease of two major
phenotypes: dysregulated proliferation, and metastatic
dissemination of transformed cells to distant sites.
Metastasis is usually (but not always) accompanied by
the acquisition by tumour cells of traits which decrease
cell-cell interactions, and increase motility and resistance
to killing by commonly used therapeutics [60]. In recent
years, it has become appreciated that mitochondria-
mediated proliferation and EMT phenotypes are in-
versely related, though regulated by common pathways
[42, 44, 45, 61, 62]. For example, analysis of transcrip-
tome data from patient tumour samples has identified
that gene sets involved in OXPHOS are commonly
changed in tumour tissues compared to normal tissue
[52]. However, the direction of change was found to be
heterogeneous, with upregulation of OXPHOS in 35% of
cancer types, and downregulated in 25% of cancer types
[52]. Interestingly, in those cancers with downregulation
of OXPHOS, EMT-related genes were the most
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significantly upregulated cohort, and these changes were
correlated with worse outcomes for patients [52]. In
agreement with this, we found that CHCHD4 expression
is also positively correlated with OXPHOS and prolifera-
tive signalling pathways (e.g. mTORC1, MYC, E2F),
while it is negatively correlated with an EMT gene signa-
ture in tumour cells, and in patient tumour samples.
While our study adds to the body of evidence supporting
this (negative) correlation, little is known about the
mechanistic relationship between these two phenotypes,
and further work will be required to understand whether
CHCHD4 influences proliferation and EMT phenotypes
through similar or distinct mechanisms, e.g. via mito-
chondrial metabolism.
Our results suggest a paradox with respect to the
importance of CHCHD4 in cancer. While we show here
that increased CHCHD4 expression correlates with
decreased EMT gene expression, we have already dem-
onstrated that above median CHCHD4 expression is cor-
related with increased tumour grade and decreased
survival [28]. Since metastatic disease is a common
feature of disease progression [60], how then can ele-
vated CHCHD4 be associated with worse outcomes for
patients in certain cancers? The answer may come from
our previous work which identified CHCHD4 as a crit-
ical regulator of HIF-mediated transcriptional responses
to hypoxia [28, 29]. The tumour microenvironment
appears to be the primary driver of EMT, since no recur-
rent mutations in EMT-regulating genes have been iden-
tified from genomic sequencing of tumour cells, unlike
the myriad mutations in oncogenes and tumour
suppressors which regulate proliferation [60]. One
significant environmental stimulus of EMT is hypoxia,
which is a common feature of tumour tissues which
outgrow their vascular supply [63, 64]. Activation of
HIF-signalling under hypoxia leads to transcriptional
activation of EMT-related genes such as vimentin and
N-cadherin, along with the suppression of MET-related
genes such as E-cadherin [65]. Furthermore, HIF-
signalling decreases mitochondrial OXPHOS by divert-
ing carbon fuels away from metabolism by the mito-
chondria [53, 66], and in some cases decreases
mitochondrial mass by suppressing mitochondrial bio-
genesis [67]. Thus, in tumours with elevated CHCHD4
expression, the increased proliferation it affords may in-
crease the size of the hypoxic niche, while simultan-
eously enhancing HIF activation, and consequently
metastatic dissemination of tumour cells. Indeed, we
have shown that silencing of CHCHD4 significantly de-
creases the hapto-migration and invasion of HCT116
cells in hypoxia [28], demonstrating the relationship be-
tween CHCHD4 and EMT phenotypes in hypoxia. It will
be important to make more detailed investigations into
the influence of CHCHD4 on hypoxia responses and
metastatic phenotypes in 3D culture models and patient
tumours, to fully understand the mechanisms by which
CHCHD4 influence metastasis.
From a therapeutic perspective, mitochondrial metab-
olism is an attractive target for treatment regimes, but is
not without significant risk of toxicity. Agents which
target the mitochondria are potently anti-proliferative,
and several small molecules are in clinical trials which
inhibit mitochondrial metabolic pathways [14, 15, 23].
The present study points to a potential complication
with this kind of therapeutic strategy however; in that
targeting mitochondrial metabolism (e.g. at CI) may
stimulate tumour cells to develop EMT characteristics
which promote metastatic dissemination. Primary
tumour cells which evade killing by chemotherapies may
therefore contribute to the metastatic population of
transformed cells, and anti-proliferative agents may in
fact contribute to disease progression and/or relapse. It
will be important to thoroughly understand the molecu-
lar mechanisms which underpin this apparent inverse re-
lationship between proliferation and EMT in order to be
able to devise treatment regimens which effectively and
systemically remove transformed cells from patients.
Conclusions
Mitochondrial metabolism plays a central role in tumour
cell proliferation. Our current study demonstrates that
the mitochondrial import protein CHCHD4 regulates
tumour cell proliferation through its effects on CI
expression and activity. Increased CI activity increases
metabolism of glutamine, and drives mTORC1-mediated
signalling. Furthermore, our study demonstrates that
CHCHD4 expression regulates the EMT phenotype of
tumour cells, and is negatively correlated with the ex-
pression of EMT genes in normoxia. Future studies will
further investigate the influence of CHCHD4 on the
metabolic landscape of cultured tumour cell lines (e.g.
nucleotide synthesis), and the proliferation and meta-
static behaviour of tumour cells in vitro and in vivo.
Methods
Cell culture
Human U2OS, HeLa, MCF7, HCT116, U87-MG and
PC3 cell lines were all obtained from American Tissue
Culture Collection (ATCC). Human osteosarcoma U2OS
control and independent clonal cell lines (WT.cl1 and
WT.cl3) expressing CHCHD4.1 cDNA (CHCHD4
(WT)-expressing cells) or CHCHD4-C66A/C68A cDNA
(CHCHD4 (C66A/C68A)-expressing cells) have been de-
scribed by us previously [29]. Human U2OS cells and
CHCHD4 (WT.cl1)-expressing cells were transfected
with either pWPI (IRES-EGFP) empty vector control or
pWPI:Ndi1(IRES-EGFP) which have been described pre-
viously [68]. Both pWPI vectors were co-transfected
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with an empty puromycin-resistance cassette containing
vector (pCMV6-A-Puro) for initial mammalian cell se-
lection. Following puromycin selection and expansion of
cell pools, pWPI-expressing cells were selected by flow
cytometric sorting of GFP-positive cells. Ndi1 (NDI1)
expression was confirmed by PCR amplification,
followed by agarose gel electrophoresis (Fig. S2d). All
cell lines were maintained in Dulbecco’s modified eagle
medium (DMEM) containing glucose (4.5 g/L) (Life
Technologies), and supplemented with 10% fetal calf
serum (FCS, SeraLabs), penicillin (100 IU/mL), strepto-
mycin (100 μg/mL) and glutamine (6 mM), all purchased
from Life Technologies. Cell lines used were authenti-
cated and routinely confirmed to be negative for any
mycoplasma contamination.
Antibodies and reagents
The rabbit polyclonal P-p70S6K (#9205), T-p70S6K
(##2708), LC3B (#3868), SDHA (#11998), COXIV
(#4850), MYC-tag (2272), Vimentin (#3932) and N-
cadherin (#13116) antibodies were purchased from Cell
Signaling Technology. The rabbit polyclonal CHCHD4
(HPA034688) antibody was purchased from Cambridge
Biosciences. The rabbit polyclonal NDUFB10
(ab196019), NDUFS3 (ab110246), UQCRC2 (ab14745)
and mouse monoclonal α-Tubulin (ab7291) and β-actin
(ab6276) antibodies were purchased from Abcam. The
goat anti-mouse IgG Alexa Fluor 568 (A11031, 1:1000)
and goat anti-rabbit IgG Alexa Fluor 488 (A11034, 1:
1000) were purchased from ThermoFisher Scientific.
The rabbit anti-puromycin antibody was a gift from Ste-
fan Marciniak (CIMR, Cambridge). Uniformly labelled
13C5-glutamine (CLM-1822-H-MPT-PK) was purchased
from CK Isotopes. Rotenone, antimycin A, DAPI nitro-
tetrazolium blue, NADH, aspartate, L-lysine, L-arginine,
L-lysine-13C6,
15N2 and L-arginine-
13C6,
15N4 (Arg-10)
were purchased from Sigma Aldrich. BAY 87-2243 was
purchased from MedChemExpress.
Gene expression analysis
Total RNA samples were isolated using the GeneElute
kit, following the manufacturer’s protocol (Sigma-Al-
drich). cDNA synthesis was carried out using the qScript
synthesis kit, following the manufacturer’s protocol
(Quantabio). mRNA expression was measured by
quantitative (Q)-PCR using SYBR Green Mastermix
(Eurogentec Ltd.) and the DNA Engine Opticon 2 sys-
tem (BioRad). Q-PCR primer sequences were as follows:
CHCHD4_F 5′-GAGCTGAGGAAGGGAAGGAT-3′; C
HCHD4_R 5′-AATCCATGCTCCTCGTATGG-3′; KR
T18_F 5′-TAGATGCCCCCAAATCTCAG-3′; KRT18_R
5′-CACTGTGGTGCTCTCCTCAA-3′; CDH2_F 5′-
AGGATCAACCCCATACACCA-3′; CDH2_R 5′-TGGT
TTGACCACGGTGACTA-3′; VIM_F 5′-GAGAACTTT
GCCGTTGAAGC-3′; VIM_R 5′-TCCAGCAGCTT
CCTGTAGGT-3′; NDI1_F 5'-AGTCAGATTCGC
TTCCACCA-3'; NDI1_R 5'-CCCAGTATCAGCACG
TTTGG-3'; ACTB_F 5′-CCCAGAGCAAGAGAGG-3′;
ACTB_R 5′-GTCCAGACGCAGGATG-3′
Mitochondrial fractionation
Crude mitochondrial fractions were prepared from
cultured cells as follows. All tubes and reagents were
pre-chilled, and all steps were carried out at 4 °C or on
ice. Cells were collected and washed twice with hom-
ogenisation buffer (HB) (250 mM Mannitol, 5 mM
HEPES (pH 7.4), 0.5 mM EGTA, in water). Pellets were
resuspended in 1 mL of HB and transferred to a chilled
glass potter. Cells were lysed with 150 strokes of potter
on ice, and 50 μL of homogenate removed for whole cell
lysate (WCL) sample. The remaining lysate was spun at
1000×g for 5 min at 4 °C. Supernatants were transferred
to fresh tubes and spun at 2000×g for 5 min at 4 °C.
Supernatants were again transferred to fresh tubes and
spun at 10,000×g for 10 min at 4 °C. Fifty microlitres of
supernatants were retained as the cytoplasm sample.
Mitochondrial pellets were washed with 2–3 mL HB and
spun at 10,000×g for 10 min at 4 °C. Supernatants were
carefully removed, and mitochondrial pellets were resus-
pended in 200 μL HB for functional assays or 200 μL 1×
Laemmli sample buffer for immunoblotting.
Sulforhodamine B viability assay
As previously described [30]. Briefly, cells were plated in
appropriate tissue culture vessels, and allowed to adhere
overnight prior to treatment. At the end of incubation,
media was removed and cells were fixed with 10%
trichloroacetic acid (TCA) for 30 min. TCA was washed
with water, wells were allowed to air dry and then an ex-
cess of 0.4% (w/v) sulforhodamine B (SRB) in 1% acetic
acid was used to stain fixed cells for > 10 min. Excess
SRB was washed off with 1% acetic acid solution. Bound
SRB was resuspended in a suitable volume of 10 mM
Tris, and absorbance of solution measured at 570 nm.
For proliferation assays, cells were plated on ‘day − 1’ in
triplicate in 12-well plates, and cultured in maintenance
DMEM overnight, after which ‘day 0’ plates fixed with
TCA. For drug sensitivity assays, cells were plated in
triplicate columns in 96-well plates, and cultured in
maintenance DMEM overnight. Appropriate wells were
dosed with serial dilutions of compounds, including ve-
hicle control wells. Cells were incubated for desired time
points followed by SRB assay. To account for any
changes in growth rate between cell lines, we also calcu-
lated the concentration for growth rate inhibition (GR)
at 50% (GR50) of the concentration at which maximum
growth is inhibited (GRmax) in the presence of drug
relative to the untreated control.
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BN-PAGE for CI activity
Samples were prepared for BN-PAGE using the Native-
PAGE Sample Preparation Kit and Protocol (Life Tech-
nologies) using a 10% dodecylmaltoside (DDM)
permeabilization solution. Samples were run on 3–12%
gradient non-reducing acrylamide gels (Life Technologies)
. For complex I activity assay, samples were run without
Coomassie blue, and gels incubated in a complex I assay
buffer (100 μM NADH and 0.5 mg/mL nitrotetrazolium
blue in 20 mM Tris) as previously described [69]. Bovine
respiratory chain complex standards were a gift from Judy
Hirst (MRC Mitochondrial Biology Unit, Cambridge, UK).
Microscopy
For immunofluorescence microscopy, cells were seeded
onto 13-mm-diameter coverslips, and after treatment,
were fixed in ice-cold methanol overnight at − 20 °C.
Coverslips were then washed with phosphate-buffered
saline (PBS). Immunostaining was carried out by serial
incubation using primary antibodies directed to
vimentin (rabbit polyclonal) and α-Tubulin (mouse
monoclonal), followed by an anti-rabbit Alexa 488 and
anti-mouse Alexa 568 secondary antibodies, as well as
DAPI (1 μg/mL). All cell imaging was carried out using
a DMI4000 B inverted microscope (Leica). Vimentin dis-
tribution analysis was carried out using Cell Profiler
Image analysis software as we have previously described
for analysis of other proteins [29]. Live cell imaging of
NADH autofluorescence was carried out according to
published protocols [70]. In brief, cells were plated on
coverslips and incubated overnight in maintenance
DMEM. Coverslips were transferred to custom imaging
rings, placed on a heated stage, then 500 μL basal assay
media (DMEM supplemented with 25 mM glucose,
1 mM pyruvate, 2 mM glutamax (Thermo Fisher
Scientific cat. no. 35050061), 10 mM HEPES, pH 7.4)
added above. Intracellular NADH fluorescence intensity
time-series were imaged using a Zeiss LSM 510 laser
scanning confocal microscope, with sample illumination
at 351 nm. Five images were taken, at 1-min intervals
under each of the following conditions: (i) basal
(untreated), (ii) 1 mM cyanide, (iii) post-wash with fresh
medium and (iv) 1 μM FCCP. Image analysis carried out
using ImageJ (NIH). Ratio of basal (untreated) NADH
pool to total intracellular NAD/NADH pool calculated
for each field of view by setting maximal NADH fluores-
cence (+cyanide) to 100, and minimal NADH fluores-
cence (+FCCP) to 0. 3 fields of view imaged per cell
line. For the scratch wound assay; cells were cultured to
100% confluency, then a single lateral scratch wound
was made in each cell monolayer using the point of a
disposable pipette tip. Wells were washed twice with
PBS to remove cell debris, and then replaced with
DMEM containing 10 μg/mL mitomycin C (Sigma
Aldrich) for the duration of the assay. Scratch wounds
were imaged in three random fields of view using trans-
mitted light and a 10x objective, at both 0 h and after 24
h culture (at 5% CO2, 37°C). Scratch wound widths were
measured using Leica Application Suite - Advanced
Fluorscence software.
Gene set analysis
Transcriptomic data generated by TCGA was accessed
from the CBioPortal data portal (http://www.cbioportal.
org/). Samples for gene expression heatmaps were
filtered by excluding samples with a z-score value for
CHCHD4 expression > 1.5. Genes for correlation
analyses were filtered by excluding samples with a p
value > 0.05. All correlations were calculated using
Spearman’s method. GSEA were carried out via the
Broad Institute analysis portal (http://software.broadin-
stitute.org/gsea/msigdb/index.jsp).
Western blot densitometry
Western blot signal intensity was measured per lane
using ImageJ (NIH) analysis software. Phosphorylated
(P)-p70S6K band intensities were normalised to total
(T)-p70S6K band intensities, then relative band inten-
sities were calculated compared to untreated control
samples for each cell line.
Metabolomics analysis
For steady-state metabolomics or metabolite tracing ex-
periments, 1 × 105 cells were seeded in 6 wells of a 6-
well plate for each cell line. After 24 h, cells were
washed twice with PBS and medium was changed with
DMEM medium containing metabolite tracers. For
glutamine tracing experiments, 6 mM 13C5-glutamine
was added to glutamine-free DMEM, together with 10%
v/v FBS. After incubation for 24 h with medium contain-
ing metabolite tracers, one well was used to estimate cell
number. To extract intracellular metabolites, cell plates
were placed on ice, washed twice with ice-cold PBS and
1 mL of metabolite extraction buffer (MEB, 50% metha-
nol, 30% acetonitrile, 20% ultrapure water, 100 ng/mL
HEPES) per 106 cells was added to each well and cells
were scraped. One cycle of freeze-thawing at − 80 °C
was performed to further lyse the cells. Intracellular
fractions were then incubated in a thermomixer (Eppen-
dorf ) at max speed for 15 min at 4 °C. Proteins were
then pelleted by centrifuging samples at 16,000×g for
10 min at 4 °C and supernatants were transferred into
glass vials and stored at − 80 °C until further analysis. Li-
quid chromatography–mass spectrometry (LC-MS) ana-
lysis was performed on a QExactive Orbitrap mass
spectrometer coupled to a Dionex UltiMate 3000 Rapid
Separation LC system (Thermo). The LC system was fit-
ted with a SeQuant ZIC-pHILIC (150 mm × 2.1 mm,
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5 mm) with the corresponding guard column (20 mm ×
2.1 mm, 5 mm) both from Merck. The mobile phase
was composed of 20 mM ammonium carbonate and
0.1% ammonium hydroxide in water (solvent A), and
acetonitrile (solvent B). The flow rate was set at 200 mL/
min with a previously described gradient [71]. The mass
spectrometer was operated in full MS and polarity
switching mode scanning a range of 50–750 m/z. Sam-
ples were randomised, in order to avoid machine drift,
and were blinded to the operator. The acquired spectra
were analysed using XCalibur Qual Browser and XCali-
bur Quan Browser software (Thermo Scientific) by refer-
encing to an internal library of compounds. Calibration
curves were generated using synthetic standards of the in-
dicated metabolites. Intensity of intracellular metabolites
were normalised on total ion sum (normalised intensity
values). For interpretation of labelling patterns, normal-
ised intensities of isotopologues were further normalised
on total isotopologue sum for each metabolite species
(proportion of total pool values).
Additional file
Additional file 1: Figure S1. CHCHD4 expression positively correlates
with OXPHOS and proliferative pathways in tumours. a Heatmap of
selected genes from HALLMARK_OXIDATIVE_PHOSPHORYLATION gene
set (Broad Institute) that are positively correlated with CHCHD4 expression
in Novartis/Broad Institute Cancer Cell Line Encyclopedia RNASeq data. n
= 967 cell lines. b Heatmap of selected genes from HALLMARK_MTORC1
_SIGNALLING gene set (Broad Institute) that are positively correlated with
CHCHD4 expression in Novartis/Broad Institute Cancer Cell Line
Encyclopedia RNASeq data. n = 967 cell lines. c Chart shows GSEA of
genes positively correlated with CHCHD4 expression in glioblastoma
patient tumours. (PDF 153 kb)
Additional file 2: Figure S2. CHCHD4-mediated tumour cell growth
and mTORC1 signalling is coupled to CI activity. a Western blots show
levels of AIF, and myc-tagged CHCHD4 in control U2OS cells, and cells
overexpressing wild-type (WT.cl1, WT.cl3) or mutant (C66A/C68A)
CHCHD4. β-Actin was used as a load control. b Chart shows mean fluor-
escence intensity of NADH in control U2OS cells, and U2OS cells express-
ing exogenous CHCHD4 (WT.cl1). Cells treated at indicated time points
with 1 mM cyanide (CN) and 1 µM FCCP. 1 image per minute, 5 images
per treatment, 3 fields of view per cell line. ±SD. n = 3. Representative im-
ages of control U2OS cells at each condition also shown. c Western blots
show levels of phosphorylated (P-) and total (T-) p70S6K, and puromycin
labelled polypeptides in control U2OS cells treated with 0, 50 or 100 nM
rotenone for 24 h, in the absence (NT) or presence of 10 mM aspartate
(+D). β-Actin was used as a load control. d Agarose gel shows expression
of NDI1 transcript in control U2OS cells and cells expressing CHCHD4
(WT.cl1), stably transfected with empty vector (pWPI) or NDI1-containing
vector (NDI1). ACTB transcript expression was used as a control.
(PDF 273 kb)
Additional file 3: Figure S3. CHCHD4 expression links growth rate to CI
activity, and correlates with tumour cell doubling time. a Chart shows
growth of tumour cell line panel treated with 500 nM BAY 87-2243 for 72
h, relative to untreated (0 nM) cells. ±SD. n = 3. b Chart shows growth of
tumour cell line panel treated with 3 µM antimycin A for 72 h, relative to
untreated (0 nM) cells. ±SD. n = 3. c Chart shows xy scatter of CHCHD4
transcript levels (RPKM - Reads Per Kilobase of transcript per Million
mapped reads), and doubling times for 368 tumour cell lines. Trend line
(dashed black), R2 value (Spearman’s correlation) and p-value of correl-
ation shown. (PDF 110 kb)
Additional file 4: Figure S4. CHCHD4-mediated tumour cell growth is
linked to CI-regulated mTORC1 signalling and amino acid metabolism.
Chart shows extracellular levels of glutamine measured in culture
medium from control U2OS cells, and cells expressing wild-type CHCHD4
(WT.cl1). Representative of 2 experiments. ±SD. n = 5. (PDF 61 kb)
Additional file 5: Figure S5. CHCHD4 regulates the EMT phenotype of
tumour cells. a-b Charts show GSEA of genes negatively correlated with
CHCHD4 expression in (a) breast cancer and (b) colon adenocarcinoma
patient tumours. c Chart shows GSEA of genes negatively correlated with
CHCHD4 expression in Novartis/Broad Institute Cell Line Encyclopedia. n =
967 cell lines. d Chart shows densitometry analysis of vimentin band
intensity from 3 independent western blots as described in Fig. 5c. ±SD.
n = 3. e Western blots show levels of E-cadherin and myc-tagged
CHCHD4 in control (Ctrl) HCT116 cells, and cells overexpressing wild-type
CHCHD4 (WT.cl8). β-Actin was used as a load control. f Western blots
show levels of E-cadherin and CHCHD4 in HCT116 cells stably expressing
control (Ctrl) shRNA or shRNA targeting CHCHD4 (CHCHD4 shRNA). β-
Actin was used as a load control. g Chart shows relative proportion of
fluorescently labelled vimentin in the perinuclear and peripheral sections
of control U2OS cells and cells overexpressing wild-type CHCHD4 (WT.cl1)
untreated (NT) or treated with 50 nM rotenone for 72 h. ±SD. n = 2 ex-
periments, 5 fields of view per condition. (PDF 175 kb)
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